Breast Cancer Advisor: O'Regan - Cancer Therapy Advisor

Breast Cancer Advisor: O’Regan

Chapter 1

2016 SABCS: Clinical Insights for Breast Cancer Treatment

In this video, Ruth M. O'Regan, MD, division head of hematology/oncology at the University of Wisconsin Carbone Cancer Center, discusses the research most likely to have a clinical impact presented at the 2016 San Antonio Breast Cancer Symposium (SABCS). Highlights include practice-changing findings from 3 trials of endocrine therapy, as well as a study about the use of everolimus with fulvestrant among patients with breast cancer.

Chapter 2

HER2-positive Metastatic and Triple-negative Cancer Treatments

In this video, Ruth M. O'Regan, MD, division head of hematology/oncology at the University of Wisconsin Carbone Cancer Center, discusses emerging treatments for patients with HER2-positive, metastatic breast cancer, as well as those for triple-negative breast cancer. CDK inhibitors and everolimus are among the treatments used for patients with HER2-positive disease, though other drugs are being studied. Dr O’Regan also discusses current research on triple-negative cancer.

Chapter 4

Emerging Medicines in Breast Cancer Treatment

In this video, Ruth M. O'Regan, MD, division head of hematology/oncology at the University of Wisconsin Carbone Cancer Center, discusses emerging treatments that are being used for patients with breast cancer, including precision medicine for individualizing cancer treatment, as well as liquid biopsies.

Next hm-playlist in Breast Cancer